EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+14.55%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.3B
AUM Growth
+$1.3B
(-0.24%)
Cap. Flow
-$181M
Cap. Flow
% of AUM
-13.88%
Top 10 Holdings %
Top 10 Hldgs %
62.01%
Holding
84
New
10
Increased
22
Reduced
31
Closed
17
Top Buys
| 1 |
GSK
GSK
|
$24.1M |
| 2 |
ZimVie
ZIMV
|
$20.7M |
| 3 |
Bausch Health
BHC
|
$12.5M |
| 4 |
Bio-Techne
TECH
|
$9.63M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$9.46M |
Top Sells
| 1 |
Inspire Medical Systems
INSP
|
$54.2M |
| 2 |
Natera
NTRA
|
$38.5M |
| 3 |
United Therapeutics
UTHR
|
$37.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$26.8M |
| 5 |
Novo Nordisk
NVO
|
$21M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
GSK
GSK
$79.9B
| $166M | 11.36% | 4,057,206 +589,126 | +17% | +$24.1M |
|
|
2
Natera
NTRA
$23.1B
| $110M | 7.57% | 870,193 -303,301 | -26% | -$38.5M |
|
3
Vera Therapeutics
VERA
$1.38B
| $90.6M | 6.21% | 2,050,157 +6,943 | +0.3% | +$307K |
|
4
Insmed
INSM
$28.8B
| $79.5M | 5.45% | 1,089,404 -66,184 | -6% | -$4.83M |
|
|
5
Syndax Pharmaceuticals
SNDX
$1.41B
| $79M | 5.41% | 4,105,313 +491,682 | +14% | +$9.46M |
|
6
Revvity
RVTY
$10.5B
| $60M | 4.11% | 469,692 +18,110 | +4% | +$2.31M |
|
|
7
Inspire Medical Systems
INSP
$2.77B
| $58.3M | 3.99% | 276,270 -256,741 | -48% | -$54.2M |
|
|
8
Teva Pharmaceuticals
TEVA
$21.1B
| $58.3M | 3.99% | 3,234,638 -1,485,822 | -31% | -$26.8M |
|
9
Community Health Systems
CYH
$387M
| $53.3M | 3.65% | 8,776,455 +738,985 | +9% | +$4.49M |
|
|
10
Bio-Techne
TECH
$8.5B
| $53M | 3.63% | 663,573 +120,529 | +22% | +$9.63M |
|
11
HCA Healthcare
HCA
$94.5B
| $52.5M | 3.59% | 129,084 -6,396 | -5% | -$2.6M |
|
|
12
United Therapeutics
UTHR
$13.8B
| $46.9M | 3.21% | 130,949 -104,402 | -44% | -$37.4M |
|
|
13
ZimVie
ZIMV
$532M
| $32.9M | 2.25% | 2,070,780 +1,303,121 | +170% | +$20.7M |
|
14
HealthEquity
HQY
$7.72B
| $26.1M | 1.79% | 319,078 -94,453 | -23% | -$7.73M |
|
15
Repligen
RGEN
$6.88B
| $24.3M | 1.67% | 163,593 -30,698 | -16% | -$4.57M |
|
16
Viatris
VTRS
$12.3B
| $20M | 1.37% | 1,726,354 +397,072 | +30% | +$4.61M |
|
17
Protagonist Therapeutics
PTGX
$3.67B
| $20M | 1.37% | 445,204 -60,632 | -12% | -$2.73M |
|
18
Celldex Therapeutics
CLDX
$1.47B
| $19.2M | 1.32% | 564,902 -68,113 | -11% | -$2.32M |
|
19
Ionis Pharmaceuticals
IONS
$6.79B
| $18.9M | 1.29% | 471,355 +14,474 | +3% | +$580K |
|
20
Viridian Therapeutics
VRDN
$1.5B
| $15.7M | 1.08% | 691,232 +123,745 | +22% | +$2.82M |
|
21
MannKind Corp
MNKD
$1.41B
| $12.5M | 0.86% | 1,992,504 -264,448 | -12% | -$1.66M |
|
|
22
Bausch Health
BHC
$2.74B
| $12.5M | 0.86% | +1,530,914 | New | +$12.5M |
|
23
Travere Therapeutics
TVTX
$1.56B
| $12.2M | 0.83% | 869,913 -221,252 | -20% | -$3.1M |
|
24
Humana
HUM
$36.5B
| $10.7M | 0.73% | 33,860 -4,163 | -11% | -$1.32M |
|
25
Danaher
DHR
$147B
| $10.7M | 0.73% | 38,429 -2,426 | -6% | -$674K |
|